Avalon GloboCare announced it has completed its early-stage trial assessing its investigational chimeric antigen receptor T-cell therapy AVA-001 as a treatment for relapsed or refractory B-cell acute lymphoblastic leukemia. Results indicated a complete remission rate of 90% within 30 days after treatment initiation, and those who attained CR were allowed to undergo allogeneic bone marrow transplants.
Avalon GloboCare reports results from CAR-T therapy trial for B-ALL
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.